HALOZYME THERAPEUTICS INC
HALONASDAQTrading Snapshot
- Day Range
- $847.17 – $865.17
- 52-Week Range
- $61.23 – $104.77
- Volume
- $2.29B
- Avg Volume
- $2.11B
- Shares Outstanding
- 118.6M
- Next Earnings
- Oct 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.64B
- Last Q Revenue
- $420M
- P/E Ratio
- 28.5
- P/S Ratio
- 7.1x
- EPS (TTM)
- $3.35
- Dividend Yield
- —
Why Investors Own HALO
- ✓High-growth profile — revenue up +29.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About HALOZYME THERAPEUTICS INC
A company profile for HALOZYME THERAPEUTICS INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know
Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance.
1 Profitable Stock to Research Further and 2 We Ignore
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks
In early August 2026, Halozyme Therapeutics, Inc. reported record second‑quarter results, with revenue rising to US$481 million and net income to US$229.91 million, and raised its full‑year 2026 revenue guidance to a range of US$1.84 billion to US$1.91 billion. The company also accelerated capital returns by completing US$750 million of share repurchases under a 2024 authorization and buying an additional US$175.01 million of stock under a new 2026 program, while signing five new...
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?
Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising full year revenue guidance and updating progress on its share repurchase programs. For the quarter ended June 30, 2026, revenue was reported at US$481 million compared with US$325.72 million for the same period a year earlier. Net income for the quarter was US$229.91 million compared with US$165.16 million a year ago. Basic...
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...
Halozyme's ENHANZE platform drives a 48% revenue surge, with new partnerships and Hypercon progress fueling a second growth engine.